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Introduction

Results

Results

AEG-1 Deletion Enhances the Antinociceptive Effects Of Morphine

• Opioids are known to induce tolerance, hyperalgesia, and high abuse
liability with prolonged usage. Therefore, it is very important to
identify novel approaches to mitigate these negative side effects.
• Morphine, a µ-opioid receptor agonist, is commonly used as an
analgesic to alleviate acute and chronic pain.
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AEG-1 KO Enhancement is OPR-Dependent
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• Astrocyte Elevated Gene-1 (AEG-1) is a multifunctional protein that
regulates inflammation, myeloid cell activity and lipid metabolism.
• AEG-1 is expressed in tissues involved pain signaling transduction,
such as the periaquaductal gray, spinal cord, and dorsal root ganglia.
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Goal of Study
• Studies have shown interactions and overlaps in cellular signaling
between the inflammatory/immune responses and the endogenous
opioid system which could suggest a role for AEG-1 in opioids
effects.
• Thus, our goal is to investigate the role of AEG-1 in morphine
mediated pharmacological effects including analgesia.

Methods
Animals:
• Adult (12-32 weeks old) AEG-1 WT or global KO male and female
mice on C57BL/6J background

The tail immersion assay was used to assess thermal nociception. We observed an enhancement in the antinociceptive effects of
morphine (10 mg/kg, i.p.) in AEG-1 KO mice in (A) an acute response time course (n=8-10/genotype/treatment for males &
females) and a (B/C) chronic morphine administration (n=6/genotype/treatment) in males and females, respectively. (B/C) AEG1 KO mice displayed reduced morphine tolerance development compared to their WT counterparts as demonstrated by the
rightward shift in the WTs. Significance determined using (A) ordinary two-way ANOVA, *significant from vehicle control,
#significant between transgenic mice in similar treatment group, α = p < 0.05. * Significant difference from vehicle controls, #
Significant difference from WT controls.

Drugs:
• Morphine Sulphate: dissolved in 0.9% saline solution.
• Naloxone Hydrochloride: dissolved in 0.9% saline solution.
Models:
• Acute response: Mice injected (i.p.) w/ drug or vehicle. Tail
immersion test was performed at 15-, 30-, 45-, 60-, 90-, and 120minutes post injection.

Results
AEG-1 Deletion Has No Effect on Hyperlocomotion or GI Transit Inhibition Induced by Morphine
A
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• Locomotor Activity Boxes: Assess spontaneous locomotion
• Charcoal Transit Assay: Assess GI transit inhibition

• AEG-1 deletion enhances the antinociceptive effects of morphine
and reduces tolerance following chronic morphine treatment.
• AEG-1 deletion does not impact morphine-induced locomotor
activity or GI transit inhibition.

• AEG-1 may function as a modulator of the endogenous opioid
system.
• Determine if other opioid drugs produce a similar enhancement in
antinociception in the AEG-1 KO mice.
• Assess the impact of AEG-1 deletion on morphine-induced
hyperalgesia.

• Chronic Treatment: Morphine tolerance induced via a 4 day
consecutive administration course (2x a day) at 20-, 40-, 40-, and 80mg/kg doses, respectively.
• Tail Immersion: Assess thermal nociception at 50.2o C

Conclusions:

Future Directions:

• Cumulative Dose Response: Mice injected increasing doses of
morphine. Tail immersion performed 20 min after each injection, and
next injection administered immediately after test.

Assays:

Conclusion / Future

• AEG-1 deletion enhances morphine antinociception in an OPRdependent manner
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To determine if the role of AEG-1 in morphine-induced antinociception is
mediated by opioid receptor (OPR) activation, AEG-1 WT and KO mice (n=811/genotype/treatment, males & females) were pre-treated with naloxone (2
mg/kg, s.c.) prior to morphine (5 mg/kg) administration. The tail immersion
assay was used to assess acute antinociception. Pretreatment with naloxone
was shown to block the enhancement of morphine thermal antinociception in
AEG-1 KO mice Significance determined using (A/B) ordinary two-way
ANOVA, α = p < 0.05.* Significant difference from vehicle controls, #
Significant difference from WT controls.

To assess the impact of AEG-1 deletion on morphine-induced hyperlocomotion and GI transit inhibition, (A) AEG-1 KO and
WT mice were injected with morphine (10 mg/kg; i.p.) and allowed to roam freely in locomotor chambers for 60 min (n=8/
genotype/treatment, males and females) and (B) AEG-1 KO and WT mice were injected with morphine and analyzed for % GI
transit (n=16/genotype/treatment, males & females). There was no significant difference in locomotor activity or % GI transit
between AEG-1 WT and KO mice treated with morphine. Significance determined using (A/B) ordinary two-way ANOVA, α =
p < 0.05. * Significant difference from vehicle controls, # Significant difference from WT controls.

• Determine if chronic administration of morphine alters AEG-1
expression and function of OPR in neurological tissues involved
in pain signaling transmission.
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